SCHEMBL140610

SCHEMBL140610

Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4ccccc4)cc32)c(C)c1C(=O)NCCN1CCCC1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 15/20 0.70
PDGFRB P09619 13/20 0.70
FGFR1 P11362 10/20 0.70
TLK2 Q86UE8 3/20 0.70
PRKAA1 Q13131 9/20 0.56
PRKAA2 P54646 8/20 0.56
FLT3 P36888 4/20 0.56
AURKB Q96GD4 4/20 0.56
EGFR P00533 4/20 0.56
MET P08581 3/20 0.56
PLK4 O00444 3/20 0.56
DCLK1 O15075 3/20 0.56
ROCK2 O75116 3/20 0.56
RPS6KA5 O75582 3/20 0.56
MAP4K4 O95819 3/20 0.56
NTRK1 P04629 3/20 0.56
INSR P06213 3/20 0.56
LCK P06239 3/20 0.56
CSF1R P07333 3/20 0.56
RET P07949 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL142633 0.92 KDR (0.66) KDRPDGFRBFGFR1TLK2PRKAA1
SCHEMBL144979 0.90 KDR (0.71) KDRPDGFRBFGFR1TLK2PRKAA1
SCHEMBL145598 0.87 FGFR1 (0.58) KDRPDGFRBFGFR1TLK2PRKAA1
SCHEMBL13755241 0.86 KDR (0.74) KDRPDGFRBFGFR1TLK2PRKAA1
SCHEMBL31672500 0.86 KDR (0.74) KDRPDGFRBFGFR1TLK2PRKAA1
SCHEMBL2114225 0.86 KDR (0.74) KDRPDGFRBFGFR1TLK2PRKAA1
SCHEMBL144568 0.86 KDR (0.55) KDRPDGFRBFGFR1TLK2PRKAA1
SCHEMBL142619 0.86 KDR (0.69) KDRPDGFRBFGFR1TLK2PRKAA1
SCHEMBL146226 0.86 GRK5 (0.59) KDRPDGFRBFGFR1TLK2PRKAA1
SCHEMBL142711 0.86 KDR (0.71) KDRPDGFRBFGFR1TLK2PRKAA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 KDR 1077/4885PDGFRB 467/4885FGFR1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.